Search research articles
Contact Us
Filters
Showing results (461-470 of 548) with videos related to
Page
of 55
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 1, 1992
Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease
F Stocchi, S Ruggieri, A Carta, et al.
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section
|
January 1, 1991
Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP
M D Taylor, M L de Ceballos, S Rose, et al.
Neuroreport
|
October 3, 1994
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole
G M MacKenzie, S Rose, P A Bland-Ward, et al.
European Journal of Pharmacology
|
April 24, 1995
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset
K K Gnanalingham, N A Milkowski, L A Smith, et al.
Journal of Neural Transmission
|
January 1, 1985
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs
N M Rupniak, M D Hall, E Kelly, et al.
Neuropharmacology
|
October 1, 1989
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin
A Ueki, P N Chong, A Albanese, et al.
European Journal of Pharmacology
|
March 3, 1992
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets
K W Lange, P A Löschmann, H Wachtel, et al.
Biochemical Pharmacology
|
December 1, 1987
Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors?
B Testa, P Jenner, G J Kilpatrick, et al.
Brain Research
|
January 15, 1990
Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
R Raisman-Vozari, J A Girault, S Moussaoui, et al.
Brain Research
|
December 16, 1996
Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera
A G Riedl, P M Watts, R J Edwards, et al.
Page
of 55
Search research articles
Search
Showing results (461-470 of 548) with videos related to
Sort By:
Page
of 55
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 1, 1992
Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease
F Stocchi, S Ruggieri, A Carta, et al.
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section
|
January 1, 1991
Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP
M D Taylor, M L de Ceballos, S Rose, et al.
Neuroreport
|
October 3, 1994
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole
G M MacKenzie, S Rose, P A Bland-Ward, et al.
European Journal of Pharmacology
|
April 24, 1995
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset
K K Gnanalingham, N A Milkowski, L A Smith, et al.
Journal of Neural Transmission
|
January 1, 1985
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs
N M Rupniak, M D Hall, E Kelly, et al.
Neuropharmacology
|
October 1, 1989
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin
A Ueki, P N Chong, A Albanese, et al.
European Journal of Pharmacology
|
March 3, 1992
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets
K W Lange, P A Löschmann, H Wachtel, et al.
Biochemical Pharmacology
|
December 1, 1987
Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors?
B Testa, P Jenner, G J Kilpatrick, et al.
Brain Research
|
January 15, 1990
Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
R Raisman-Vozari, J A Girault, S Moussaoui, et al.
Brain Research
|
December 16, 1996
Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera
A G Riedl, P M Watts, R J Edwards, et al.
Page
of 55